Jönsson P E, Malmberg M, Bergljung L, Ingvar C, Ericsson M, Ryden S, Nilsson I, Terje I J
Department of Surgery, Helsingborg Hospital, Sweden.
Anticancer Res. 1991 Mar-Apr;11(2):873-5.
Thirty-five (34 evaluable) consecutive postmenopausal women with estrogen receptor positive (greater than or equal to 10 fmol/mg) or unknown advanced breast cancer were treated with high dose toremifene in a phase II study. All patients had progressed during prior adjuvant or palliativ antiestrogen treatment. The dose of toremifene was 240 mg per day. No complete or partial responders were registered. Nine patients (26%) were considered to have stable disease (NC). The time to progression for these patients was 5-27+ months with a mean time of twelve months and median time of eight months. Two patients are still on treatment after twelve and 24 months respectively. There seems to be a relationship with receptor value; however, there are two few patients for a safe statistical analysis. The side effects were insignificant. The conclusion is that the efficiency of toremifene as second line hormonal treatment is restricted, although it may be one additional choice.
在一项II期研究中，35名（34名可评估）连续的雌激素受体阳性（大于或等于10 fmol/mg）或未知的绝经后晚期乳腺癌女性患者接受了高剂量托瑞米芬治疗。所有患者在先前的辅助或姑息性抗雌激素治疗期间均出现病情进展。托瑞米芬的剂量为每日240毫克。未记录到完全或部分缓解者。9名患者（26%）被认为病情稳定（NC）。这些患者的疾病进展时间为5 - 27 +个月，平均时间为12个月，中位时间为8个月。分别有2名患者在12个月和24个月后仍在接受治疗。似乎与受体值存在关联；然而，患者数量过少，无法进行可靠的统计学分析。副作用不明显。结论是，托瑞米芬作为二线激素治疗的疗效有限，尽管它可能是一种额外的选择。
